MDC/CCL22 intrathecal levels in patients with multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 4, 2008, Pages 547-549

  Galimberti, Daniela ^a   Fenoglio, C ^a   Comi, C ^b   Scalabrini, D ^a   De Riz, M ^a   Leone, M ^b   Venturelli, E ^a   Cortini, F ^a   Piola, M ^a   Monaco, F ^b   Bresolin, N ^a   Scarpini, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Cerebrospinal fluid; MDC CCL22; Multiple sclerosis

Indexed keywords

CYTOKINE; MACROPHAGE DERIVED CHEMOKINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; SEX DIFFERENCE; STUDENT T TEST; TH2 CELL;

ADULT; CELL MOVEMENT; CHEMOKINE CCL22; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; SEX CHARACTERISTICS; TH2 CELLS;

EID: 46749157569     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507084268     Document Type: Article

References (11)

1. Piccio L, Rossi B, Scarpini E, Laudanna C, Giagulli C, Issekutz AC et al. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric Gi-linked receptors. J Immunol 2002; 168: 1940-49.
2. Galimberti D, Bresolin N, Scarpini E. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. Expert Rev Neurotherapeutics 2004; 4(3): 439-53.
3. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
4. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-8.
5. Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002; 195: 41-6.
6. Columba-Cabezas S, Serafini B, Ambrosini E, Sanchez M, Penna G, Adorini L et al. Induction of macrophage-derived chemokine/ CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 2002; 130: 10-21.
7. Cronshaw DG, Kouroumalis A, Parry R, Webb A, Brown Z, Ward SG. Evidence that phospholipase-C-dependent, calcium-independent mechanisms are required for directional migration of T-lymphocytes in response to the CCR4 ligands CCL17 and CCL22. J Leukoc Biol 2006; 79(6): 1369-80.
8. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for MS. Ann Neurol 2001; 50: 121-7.
9. Lublin FD, Reingold SC for the National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis; results of an international survey. Neurology 1996; 46(4): 907-11.
10. Zaffaroni M, Ghezzi A. The prognostic value of age, gender, pregnancy and endocrine factors in multiple sclerosis. Neurol Sci 2000; 21(4 Suppl 2): S857-60.
11. Ambrosini E, Aloisi F. Chemokines and glial cells: a complex network in the central nervous system. Neurochem Res 2004; 29(5): 1017-38.